Discover the science behind Tesamorelin, a research peptide targeting visceral fat and promoting health span. Kris Gethin breaks down its mechanisms, research findings, and implications for fat distribution and longevity.

Tesamorelin is a synthetic analog of growth hormone release hormone (GHRH), stimulating the pituitary to release endogenous growth hormone rather than supplying synthetic GH.
It primarily targets deep visceral fat, especially around organs, instead of just superficial subcutaneous fat.
Visceral fat is linked to metabolic diseases, inflammation, insulin resistance, and overall aging; reducing it can extend health span.
Research shows Tesamorelin reduces visceral fat by approximately 14-18% over 26 weeks without significant weight change.
Unlike appetite suppressants like GLP-1 agents, Tesamorelin is considered weight-neutral, aiming for fat redistribution rather than broad weight loss.
The effects on body composition include improved fat distribution, preservation of lean mass, and healthier metabolic markers.
It can influence glucose tolerance and may cause fluid retention, joint pain, or injection site reactions, especially in older or metabolic-compromised individuals.
Optimizing lifestyle factors such as sleep, nutrition, and stress management is crucial, as environment impacts visceral fat accumulation.
Measuring waist circumference, visceral fat via imaging, blood markers, and metabolic health indicators are essential for tracking progress.
Use of peptides like Tesamorelin should be under medical supervision within a broader health and lifestyle strategy.

Timestamps:

00:00 - Introduction to Kris Gethin and peptide content channels 00:27 - What is Tesamorelin and its clinical relevance 00:56 - Mechanism: GHRH analog stimulating growth hormone release 01:23 - Differentiating Tesamorelin from other peptides and its origin 01:50 - Impact on visceral and liver fat, and fat loss models 02:20 - Growth hormone axis and visceral fat interaction 02:44 - Education disclaimer and medical considerations 03:14 - Historical context: HIV-related lipodystrophy and fat redistribution 04:12 - Visceral vs subcutaneous fat differences 04:42 - Psychological and health impacts of visceral fat 05:10 - How Tesamorelin targets internal fat and body composition 05:37 - Fat loss measurement—imaging and metabolic markers 06:06 - Clinical trial outcomes: visceral fat reduction statistics 06:33 - Fat redistribution versus scale weight changes 07:00 - Growth hormone effects on adipose tissue and fat mobilization 07:29 - Localized fat loss and research evidence 07:58 - Impact on organs around visceral fat 08:24 - Clinical trial insights on visceral fat change over 26 weeks 08:53 - Quantitative results: visceral fat reduction percentages 09:21 - Fat loss success indicators: visceral fat, waist size, metabolics 09:49 - Why weight-neutral interventions are vital for health span 10:18 - Visceral fat's role in metabolic aging and liver health 10:45 - External factors influencing visceral fat and lifestyle importance 11:15 - Liver fat, insulin resistance, and metabolic health 11:45 - Impact on HIV-associated liver issues and relevance to non-HIV populations 12:14 - Liver fat's role in glucose regulation and overall health 12:42 - The importance of measuring internal fat and metabolic health 13:10 - How lifestyle interacts with peptide effects and fat storage 13:38 - The complex role of growth hormone and IGF-1 in body health 14:06 - Risks, side effects, and precautions with Tesamorelin 14:36 - The importance of medical oversight and blood work monitoring 15:06 - Peptides as part of broader lifestyle strategies 15:35 - Influence of environment and lifestyle on visceral fat 16:04 - The significance of fat distribution for health and appearance 16:33 - Misconceptions: fat loss vs fat redistribution and muscle preservation 17:02 - The balance of growth hormone signaling and metabolic risks 17:31 - Regulating GH pathways for optimal health outcomes 18:00 - Side effects: fluid retention, joint pain, sleep issues 18:29 - Medical considerations: conditions requiring caution 18:58 - The impact of growth hormone on glucose metabolism 19:27 - Reversibility: why maintaining lifestyle is key to permanence 19:54 - The importance of measuring progress with tools beyond the scale 20:22 - Integrating blood tests, imaging, and lifestyle logs 20:49 - Systemic approach: nutrition, training, stress, sleep 21:18 - Visceral fat as a reflection of metabolic health 21:46 - Peptides as lifestyle adjuncts, not standalone solutions 22:16 - Why deep visceral fat should be prioritized for health risk reduction 22:46 - Visuals of fat distribution and fat loss versus muscle depletion 23:15 - Peptides' role in health span, not just aesthetics 23:44 - Comparing Tesamorelin with traditional growth hormone therapies 24:12 - Muscle gain limitations and realistic expectations 24:39 - Peptides as tools for fat and metabolic health, not muscle building 25:09 - Broader issues: environment, lifestyle, and societal factors in obesity 25:38 - The importance of healthy habits for lasting results 26:05 - Changing environment to sustain fat loss gains 26:33 - Focus on targeted fat loss and biological change over scale weight 27:01 - Practical advice: measure waist, blood markers, and lifestyle factors 27:31 - Summary: deep visceral fat as a sign of aging; the role of Tesamorelin 27:59 - Trusted peptide suppliers and quality control 28:28 - Final thoughts and encouragement for responsible research and use

Resources & Links:

Biohacked AF Community & Education
Nova Prime Labs (preferred peps)

Connect with Kris Gethin: